EW Healthcare Partners - Portfolio

Symphogen A/S

Develops recombinant antibody mixtures for the treatment and prevention of disease

Robust pipeline with development stage candidates across multiple indications
Closed $70M private financing in October 2015 to continue developing pipeline
Results from Phase II trials in 2016 - 2017 a key milestone that could trigger an acquisition of the company
Strong interest from strategics could result in sale of development programs for significant up-front payment plus milestones